Open your account
Empower yourself with cutting-edge tools, expert insights, and unrivaled features.
Summary
Sahajanand Medical Technologies Limited (SMT), a global medical device manufacturer specializing in vascular intervention (VI) and structural heart (SH) devices, is launching its Initial Public Offering (IPO). The offer comprises a 100% Offer for Sale (OFS) of up to 27,644,231 Equity Shares of face value ₹1 each by promoter and investor selling shareholders. Bidding is open from 15 Oct '26 to 19 Oct '26 with a price range of ₹327 - ₹344 per share. In Fiscal 2025, SMT achieved ₹10,248.79 million in revenue from operations—a steady increase from ₹9,016.04 million in FY24, and registered a net profit after tax of ₹251.52 million. Dive into our comprehensive guide to explore SMT's market presence, product portfolio, and long-term growth prospects.
The bidding for the Sahajanand Medical Technologies Limited (SMT) IPO is scheduled for 15 Oct '26 to 19 Oct '26. If you closely track the Indian healthcare and medical devices sector, SMT's IPO marks an important milestone in the primary market landscape.
Why Market Trackers Are Watching This IPO: SMT is a research-driven medical devices company focused on high-margin Vascular Intervention (VI) and Structural Heart (SH) products. Driven by its flagship Supraflex Cruz product and rapid international expansion into 76 countries, the company reported a robust revenue from operations of ₹10,248.79 million in Fiscal 2025.
SMT IPO Window & Offer Structure
- Bidding Dates: 15 Oct '26 - 19 Oct '26.
- Price Range: ₹327 - ₹344 per equity share (Face Value: ₹1 per share).
- Total Issue Size: Up to 27,644,231 Equity Shares.
- Fresh Issue & OFS: 100% Offer for Sale (OFS) of up to 27,644,231 Equity Shares; No Fresh Issue.
- Employee Reservation: Reserved for Eligible Employees with an applicable Employee Discount.
- Listing On: BSE Limited and National Stock Exchange of India Limited (NSE).
Objects of the Offer: How Will Proceeds Be Utilized?
100% Offer for Sale. Because this IPO consists entirely of an Offer for Sale, the utilization of proceeds is straightforward:
- Selling Shareholders: The Selling Shareholders will be entitled to the entire proceeds of the Offer after deducting the Offer expenses and relevant taxes.
- Company Proceeds: SMT will not receive any direct proceeds from the Offer for Sale.
- Listing Benefits: The primary corporate object is to achieve the benefits of listing the Equity Shares on the Stock Exchanges and enhancing the company's brand image.
What Are the Key Drivers for SMT's Performance?
The global vascular devices market continues to witness consistent growth driven by the increasing prevalence of cardiovascular diseases. SMT has positioned itself strongly within these fast-growing medical segments globally.
Here are the critical factors influencing SMT's operational performance:
- Core Vascular Intervention Dominance: VI devices contributed to 65.86% of the total revenue from operations in Fiscal 2025.
- Flagship Product Strength: Sales of the Supraflex Cruz stent contributed to 42.06% of the company's total revenue from operations in Fiscal 2025.
- Global Footprint: Significant international traction, with revenues from outside India accounting for 68.71% of total revenue from sales in Fiscal 2025.
- Strong Distribution Network: An extensive sales network spanning 103 distributors in India and 260 distributors internationally as of March 31, 2025.
- In-House Manufacturing: Operates advanced manufacturing facilities located in Surat SEZ (India), Hyderabad (India), and Nonthaburi (Thailand).
A Quick Look at Financial Highlights (FY23 - FY25)
To evaluate SMT's financial health, let's review the restated consolidated financial figures over the last three financial years.
| Financial Metric (in ₹ million) | FY25 | FY24 | FY23 | Key Details |
|---|---|---|---|---|
| Revenue from Operations | 10,248.79 | 9,016.04 | 7,955.49 | Steady upward YoY growth driven by both domestic and export market expansions. |
| Restated Profit / (Loss) After Tax | 251.52 | (73.54) | 119.34 | Robust turnaround in PAT for FY25 following a net loss year in FY24. |
| Net Worth | 5,452.32 | 5,263.03 | 5,392.12 | Consolidated net worth attributable to the owners of the company. |
| Total Borrowings | 2,249.57 | 1,752.69 | 1,321.81 | Borrowings have increased over the periods to support working capital and operations. |
The Financial Takeaway:
SMT achieved healthy top-line expansion across multiple geographical regions and returned to solid profitability in Fiscal 2025 following strategic R&D investments and clinical trial completions.
Category & Product Portfolio Overview
| Product Category | FY25 Revenue (₹ mn) | % Share of Revenue | Strategic Highlights |
|---|---|---|---|
| Vascular Intervention (VI) Devices | 6,749.70 | 65.86% | Includes high-demand coronary stents and coronary balloons globally. |
| Supraflex Cruz (Specific Stent) | 4,310.31 | 42.06% | Flagship biodegradable polymer-based drug-eluting stent. Heavily relied upon for revenue growth. |
Key Monitorables: Investors will closely track the concentration of revenue heavily leaning on the Supraflex Cruz, as well as the transition of CE certifications under the new EU Medical Device Regulations (MDR).
What are the Long-Term Growth Pillars?
Looking Ahead
Sahajanand Medical Technologies Limited's strategic focus on the high-margin cardiovascular segment positions it favorably to capitalize on rising global healthcare demands.
By scaling their manufacturing capacities, managing an expansive distribution network, and leaning heavily into life-saving innovations like Structural Heart devices, SMT aims to drive long-term, sustainable commercial success.
Want to Learn More About the Sahajanand Medical Technologies IPO?
Explore the live IPO offering page for detailed financial analysis, management discussion, growth strategy, and issue details.
Read more
Disclaimer: This article is for information and educational purposes only. It does not constitute investment advice, trading advice, or a recommendation to buy, sell, or hold any security. Investors and traders should consult with a certified financial advisor before making any investment decisions. AI tools may have been used to assist in the creation of this article.